Rafarma Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAFA research report →
Companyrafarma.si
Rafarma Pharmaceuticals, Inc. , a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules.
- CEO
- Sergey Brusnitsin
- IPO
- 2012
- Employees
- 700
- HQ
- Sandy, UT, US
Price Chart
Valuation
- Market Cap
- $5.27M
- P/E
- 23.83
- P/S
- 0.60
- P/B
- 0.51
- EV/EBITDA
- 16.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 6.37%
- Op Margin
- 4.07%
- Net Margin
- 2.50%
- ROE
- 2.13%
- ROIC
- 2.43%
Growth & Income
- Revenue
- $9.18M · 1.09%
- Net Income
- $349.00K · 31.20%
- EPS
- $0.00 · 33.33%
- Op Income
- $489.00K
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.11
- 52W Low
- $0.00
- 50D MA
- $0.06
- 200D MA
- $0.05
- Beta
- 0.43
- Avg Volume
- 11.51K
Get TickerSpark's AI analysis on RAFA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RAFA Coverage
We haven't published any research on RAFA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RAFA Report →